176 related articles for article (PubMed ID: 8161288)
1. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
Marder SR; Wirshing WC; Van Putten T; Mintz J; McKenzie J; Johnston-Cronk K; Lebell M; Liberman RP
Arch Gen Psychiatry; 1994 Apr; 51(4):280-7. PubMed ID: 8161288
[TBL] [Abstract][Full Text] [Related]
2. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
3. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia.
Marder SR; Wirshing WC; Mintz J; McKenzie J; Johnston K; Eckman TA; Lebell M; Zimmerman K; Liberman RP
Am J Psychiatry; 1996 Dec; 153(12):1585-92. PubMed ID: 8942455
[TBL] [Abstract][Full Text] [Related]
4. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
Kane JM; Rifkin A; Quitkin F; Nayak D; Ramos-Lorenzi J
Arch Gen Psychiatry; 1982 Jan; 39(1):70-3. PubMed ID: 6275811
[TBL] [Abstract][Full Text] [Related]
5. Diazepam treatment of early signs of exacerbation in schizophrenia.
Carpenter WT; Buchanan RW; Kirkpatrick B; Breier AF
Am J Psychiatry; 1999 Feb; 156(2):299-303. PubMed ID: 9989567
[TBL] [Abstract][Full Text] [Related]
6. Costs and benefits of two doses of fluphenazine.
Marder SR; Van Putten T; Mintz J; McKenzie J; Lebell M; Faltico G; May PR
Arch Gen Psychiatry; 1984 Nov; 41(11):1025-9. PubMed ID: 6437365
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
[TBL] [Abstract][Full Text] [Related]
8. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
Marder SR; Aravagiri M; Wirshing WC; Wirshing DA; Lebell M; Mintz J
Schizophr Res; 2002 Jan; 53(1-2):25-30. PubMed ID: 11728835
[TBL] [Abstract][Full Text] [Related]
9. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate.
Schooler NR; Levine J; Severe JB; Brauzer B; DiMascio A; Klerman GL; Tuason VB
Arch Gen Psychiatry; 1980 Jan; 37(1):16-24. PubMed ID: 7352836
[TBL] [Abstract][Full Text] [Related]
10. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data.
Rifkin A; Quitkin F; Klein DF
Arch Gen Psychiatry; 1977 Oct; 34(10):1215-9. PubMed ID: 199129
[TBL] [Abstract][Full Text] [Related]
11. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
Odejide OA; Aderounmu AF
J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
[TBL] [Abstract][Full Text] [Related]
12. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
Kane JM; Rifkin A; Woerner M; Reardon G; Sarantakos S; Schiebel D; Ramos-Lorenzi J
Arch Gen Psychiatry; 1983 Aug; 40(8):893-6. PubMed ID: 6347119
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
[TBL] [Abstract][Full Text] [Related]
14. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.
Wistedt B
Acta Psychiatr Scand; 1981 Jul; 64(1):65-84. PubMed ID: 7032224
[TBL] [Abstract][Full Text] [Related]
15. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.
Marder SR; Van Putten T; Mintz J; Lebell M; McKenzie J; May PR
Arch Gen Psychiatry; 1987 Jun; 44(6):518-21. PubMed ID: 3555385
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT
Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557
[TBL] [Abstract][Full Text] [Related]
17. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.
Kane JM; Rifkin A; Quitkin F; Nayak D; Saraf K; Ramos-Lorenzi JR; Klein DF; Sachar EJ
Psychiatry Res; 1979 Dec; 1(3):341-8. PubMed ID: 233160
[TBL] [Abstract][Full Text] [Related]
18. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Dellva MA; Tran P; Tollefson GD; Wentley AL; Beasley CM
Psychiatr Serv; 1997 Dec; 48(12):1571-7. PubMed ID: 9406266
[TBL] [Abstract][Full Text] [Related]
19. The use of depot neuroleptics: clinical experience in the United States.
Kane JM
J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987
[TBL] [Abstract][Full Text] [Related]
20. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.
Hogarty GE; Schooler NR; Ulrich R; Mussare F; Ferro P; Herron E
Arch Gen Psychiatry; 1979 Nov; 36(12):1283-94. PubMed ID: 227340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
